EOC237 / EOC Pharma - LARVOL DELTA

A Study of EOC237 in Patients With Advanced Solid Tumor (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

A Study of EOC237 in Patients With Advanced Solid Tumor (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd

Metastases • New P1 trial • Oncology • Solid Tumor

Eddington-Jingang’s application for the first clinical trial of a CDK7 inhibitor in China was accepted (Sina Corp) - "According to the official website of the Center for Drug Evaluation (CDE) of the State Drug Administration, on February 13, the clinical trial application for an oral, highly selective CDK7 inhibitor EOC237 of Eddington Jingang Pharmaceutical was officially accepted....This year, EOC237 plans to enter Phase I clinical trials, and the indication is advanced solid tumors. As no clinical trial application has been submitted for the same target molecule in China, EOC237 is expected to become the first CDK7 inhibitor to enter the clinical trial stage in China."

New P1 trial • Oncology • Solid Tumor